Information Provided By: 
Fly News Breaks for August 20, 2015
MNTA
Aug 20, 2015 | 07:31 EDT
Bernstein analyst Ronny Gal sees a "significant opportunity" in shares of Momenta Pharmaceuticals over the next few months. Copaxone sales should prove durable as a competing approval is unlikely until mid-2016, Gal tells investors in a research note. The analyst sees limited share downside before year-end and raised his price target for the stock to $31. He keeps an Outperform rating on Momenta.
News For MNTA From the Last 2 Days
There are no results for your query MNTA
